Tagged with IT

UK Although biotech financing in the UK took a hit last year in large part thanks to uncertainty around Brexit, 2019 was still the British industry’s third-best year on record.   The UK’s exit from the European Union looms large over all British industries, including pharmaceuticals and biotech. Unsurprisingly, therefore, UK…

Opinion Health Catalyst’s Elia Stupka explains why and how patients must be kept at the centre of the healthcare systems of the future, even as they become increasingly data-driven.   Healthcare data is seen by many as the ‘new goldmine,’ with many businesses in this field evaluated and sold at a significant…

Webinar With the recent publication of Ten years on: Measuring the Return from Pharmaceutical Innovation 2019, PharmaBoardroom has teamed up with Deloitte to offer its readers an exclusive webinar on The Future of Biopharma.   On 25th February 2020, join us to discuss the major trends that have impacted the biopharma industry over the past ten years, the…

China Jens Ewert, Life Science and Health Care Industry Leader at Deloitte China, shares his perspectives on the growth of China’s Life Sciences and Healthcare market, the strong presence of Deloitte within China as a consulting firm, the recent trends of the market and their commitment to delivering comprehensive solutions to…

China As patients and consumers grow more educated and proactive in managing their own health and wellbeing, new ventures are hoping to serve their needs in not just prophylactic but also preventative health. HiNounou is a nifty little start-up based in Shanghai seeking to redefine the health management app.   Health…

Hungary After years of planning and collaboration with various stakeholders, in 2017 the Hungarian government launched the Electronic Health Service Area (EESZT): a centralized database of patient records and health interventions with the aim of bringing Hungary in line with other countries at the forefront of digital healthcare   The Road…

Hungary Anna Wienner, general manager of IBSA Hungary, gives an update on the recent activities and achievement of the affiliate since her previous interview in 2016. Furthermore, Wienner goes on to offer her expert insights into key trends impacting the Hungarian healthcare ecosystem in areas such as in vitro fertilization, market…

Hungary Dr Miklós Kellermayer elaborates on his priorities to implement a more practical, experience-focused curriculum as the recently appointed Dean of the Faculty of Medicine of Semmelweis University. Dr Kellermayer goes on to speak about the university’s critical role within the Hungarian healthcare ecosystem and the initiatives taking place during the…

Puerto Rico After Hurricane Maria hit Puerto Rico in 2017, its infrastructure was left severely damaged. CMA, one of the island’s premiere architecture and engineering firms, has been working on reconstruction ever since. Jorge Tirado, CMA’s managing partner, describes how the company has managed to become the go-to firm for the pharma…

Hungary Dr. György Bagdy, professor and former vice rector at Semmelweis University, shares his insights on the longstanding history of pharmacology in Hungary, the key strengths of the country in the field of neuroscience, and the future outlook of a more collaborative and innovation-focused research landscape.   Hungary has the knowledge…

Collaboration With sustainable development goals in mind, the global umbrella pharmaceutical association IFPMA has recently launched a platform that fosters collaboration with the aim of tackling problems related to health and equality through partnerships between biopharma companies, governments, academia and other local institutions.    Effective partnerships will help our innovations to…

China China’s new Amended Drug Administration Law is being enacted to strengthen and streamline its regulation of the pharmaceutical industry as well as address prominent problems such as counterfeit drugs, substandard drugs and high drug prices. Fangda Partners’ Josh Shin explains how the new law strengthens penalties for counterfeit and substandard…